Valuation: Novavax, Inc.

Market Cap 1.78B 1.58B 1.48B 1.35B 2.54B 172B 2.58B 17.92B 6.94B 87.43B 6.69B 6.55B 281B P/E 2026 *
-17.3x
P/E 2027 * -48.2x
Enterprise Value 2B 1.78B 1.66B 1.52B 2.85B 193B 2.89B 20.12B 7.79B 98.17B 7.52B 7.35B 315B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 7.84x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.78B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.69%-4.96%+28.26%+34.82% 44.25B
+0.69%+3.90%+352.78%+693.45% 43.99B
-1.93%+0.10%+7.51%+101.87% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.87%-9.14%-25.01%+335.32% 24.93B
Average -1.08%+1.97%+54.77%+160.80% 44.09B
Weighted average by Cap. +0.28%+1.83%+59.03%+151.93%

Financials

2026 *2027 *
Net sales 373M 331M 310M 282M 531M 35.91B 539M 3.75B 1.45B 18.29B 1.4B 1.37B 58.74B 266M 236M 221M 201M 379M 25.63B 385M 2.67B 1.04B 13.05B 999M 978M 41.92B
Net income -108M -95.52M -89.33M -81.4M -153M -10.35B -155M -1.08B -418M -5.27B -404M -395M -16.94B -37.93M -33.69M -31.5M -28.71M -54.05M -3.65B -54.79M -381M -148M -1.86B -142M -139M -5.97B
Net Debt 219M 195M 182M 166M 312M 21.09B 316M 2.2B 852M 10.74B 822M 804M 34.49B 303M 269M 252M 230M 432M 29.19B 438M 3.05B 1.18B 14.87B 1.14B 1.11B 47.75B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-